SEC For	m 4
---------	-----

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

Estimated average burden	
hours per response:	0.5

7

1. Name and Address of Reporting Person [*] DEMAREE JOHN			2. Issuer Name and Ticker or Trading Symbol <u>G1 Therapeutics, Inc.</u> [GTHX]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
DEMAREE .	JOHN		L J		Director	10% Owner				
(Last)	(First)	(Middle)		X	Officer (give title below)	Other (specify below)				
()	()	, ,	3. Date of Earliest Transaction (Month/Day/Year)	1	Chief Commercial	Officer				
C/O G1 THERA DR.	APEUTICS, 79 TW	ALEXANDER	01/02/2019							
4501 RESEARC	CH COMMONS, S	UITE 100								
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line)	dual or Joint/Group Filing (C	Check Applicable				
RESEARCH				X	Form filed by One Reporti	ng Person				
TRIANGLE PARK	NC	27709			Form filed by More than O Person	one Reporting				
(City)	(State)	(Zip)								
	Tá	able I - Non-Deriva	tive Securities Acquired, Disposed of, or Benefic	cially C	Dwned					

r. 3) 2. Transaction 2A. Deemed 3. 4. Securities Acquired (A) or 5. Amount of 6. Ownership

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	if any	Date, Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			Securities Beneficially Owned Following	(D) or Indirect	7. Nature of Indirect Beneficial Ownership	
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

										,					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exerc Expiration Da (Month/Day/Y	ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Options (Right to Buy)	\$19.56	01/02/2019		A		60,000		(1)	01/02/2029	Common Stock	60,000	\$0.00	60,000	D	

Explanation of Responses:

1. The shares underlying this option vest as to 25% of the shares on January 02, 2020, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.

Remarks:

<u>/s/ James Stillman Hanson,</u> <u>attorney-in-fact</u>

01/02/2019

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 \ast If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.